{"id":5678,"date":"2023-09-04T03:17:19","date_gmt":"2023-09-04T03:17:19","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/rider-phantom-pet-ct\/"},"modified":"2023-09-13T12:02:40","modified_gmt":"2023-09-13T12:02:40","slug":"rider-phantom-pet-ct","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/rider-phantom-pet-ct\/","title":{"rendered":"RIDER-PHANTOM-PET-CT"},"featured_media":0,"template":"","citation-tax":[],"cancer_types":["Phantom"],"citations":[4618,2925],"collection_doi":"10.7937\/K9\/TCIA.2015.8WG2KN4W","collection_download_info":"Click the Versions tab for more info about data releases.","collection_downloads":[5239,5240,5241],"full_export":"

Summary<\/h2>The RIDER Phantom PET-CT collection consists of repeat measurement PET\/CT phantom scan collections carried out under the aegis of the Society of Nuclear Medicine (SNM) to discern the uniformity of clinical imaging instrumentation at various sites. They were obtained in cooperation with SNM as a resource for increased quantitative understanding of machine acquisition, analytic reproducibility and image processing.<\/span>

The phantom was manufactured by Sanders Medical (www.sandersmedical.com<\/a>) in December of 2006. The phantom was based on a NEMA NU-2 IQ phantom (manufactured by Data Spectrum, Durham NC), but with the central 5 cm diameter 'lung' cylinder of the IQ phantom removed. In addition the two larger fillable spheres were changed to hot spheres, as opposed to cold spheres as in the NEMA NU-2 specifications. Nominal target\/background ratio was 4:1 with the initial background activity level set to be equivalent to 15 mCi in a 70 Kg patient, With the 271 day half-life of Ge-68 after 6 months the activity will be about 9.5 mCi. After a year it was 6 mCi.<\/p>

About the RIDER project<\/h3>

The Reference Image Database to Evaluate Therapy Response (RIDER) is a targeted data collection used to generate an initial consensus on how to harmonize data collection and analysis for quantitative imaging methods applied to measure the response to drug or radiation therapy. \u00a0The National Cancer Institute (NCI) has exercised a series of contracts with specific academic sites for collection of repeat "coffee break," longitudinal phantom, and patient data for a range of imaging modalities (currently computed tomography [CT]\u00a0positron emission tomography [PET]\u00a0CT, dynamic contrast-enhanced magnetic resonance imaging [DCE MRI], diffusion-weighted [DW] MRI) and organ sites (currently lung, breast, and neuro). <\/span>The methods for data collection, analysis, and results are described in the new Combined RIDER White Paper Report (Sept 2008):<\/p>